Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008)

(2008) G. T. HO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS